A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti−PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy


Condition: Renal Cell Carcinoma

Intervention:

  • Drug: Atezolizumab
  • Other: Placebo

Purpose: This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following nephrectomy.

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT03024996

Sponsor: Hoffmann-La Roche

Primary Outcome Measures:

  • Measure: IRF-assessed Disease-Free Survival (DFS)
  • Time Frame: From Baseline until first documented recurrence event (up to approximately 88 months)
  • Safety Issue:

Secondary Outcome Measures:

  • Measure: Overall Survival
  • Time Frame: From Baseline up to death due to any cause (up to approximately 88 months)
  • Safety Issue:
  • Measure: Investigator-assessed DFS
  • Time Frame: From Baseline up to first occurence of event by investigator assessment (up to approximately 88 months)
  • Safety Issue:
  • Measure: IRF-assessed DFS in Participants With Tumor-Infiltrating Immune Cell (IC) 1/2/3
  • Time Frame: From Baseline until first occurrence of DFS event (up to approximately 88 months)
  • Safety Issue:
  • Measure: Investigator-assessed DFS in Participants With Tumor-Infiltrating IC 1/2/3
  • Time Frame: From Baseline until first occurrence of DFS event (up to approximately 88 months)
  • Safety Issue:
  • Measure: Disease-Specific Survival
  • Time Frame: From Baseline up to death due to RCC (up to approximately 88 months)
  • Safety Issue:
  • Measure: Distant Metastasis-Free Survival
  • Time Frame: From Baseline up to date of diagnosis of distant metastases or death due to any cause (up to approximately 88 months)
  • Safety Issue:
  • Measure: Percentage of Participants Who Are Alive and IRF-assessed Recurrence Free at Year 3
  • Time Frame: Year 3
  • Safety Issue:
  • Measure: Percentage of Participants Who Are Alive and Investigator-assessed Recurrence Free at Year 3
  • Time Frame: Year 3
  • Safety Issue:
  • Measure: Percentage of Participants With Adverse Events
  • Time Frame: From Baseline up to 90 days after last dose of study drug or until initiation of new systemic anti-cancer therapy, whichever occurs first (last dose = up to approximately 1 year)
  • Safety Issue:
  • Measure: Maximum Serum Concentration (Cmax) of Atezolizumab
  • Time Frame: Predose (Hour[hr]0), 0.5 hr after end of infusion (infusion duration=1 hr) on Cycle 1 Day 1; predose (hr 0) on Day 1 of Cycles 2, 3, 4, 8; at treatment discontinuation (up to 1 year); 90-120 days after last dose (last dose = up to 1 year) (Cycle=21 days)
  • Safety Issue:
  • Measure: Minimum Serum Concentration (Cmin) of Atezolizumab
  • Time Frame: Predose (Hour[hr]0), 0.5 hr after end of infusion (infusion duration=1 hr) on Cycle 1 Day 1; predose (hr 0) on Day 1 of Cycles 2, 3, 4, 8; at treatment discontinuation (up to 1 year); 90-120 days after last dose (last dose = up to 1 year) (Cycle=21 days)
  • Safety Issue:
  • Measure: Percentage of Participants With Anti-Therapeutic Antibodies (ATA) to Atezolizumab
  • Time Frame: Predose (hr 0) on Day 1 of Cycles 1, 2, 3, 4, 8; at treatment discontinuation (up to 1 year); 90-120 days after last dose (last dose = up to 1 year) (Cycle=21 days)
  • Safety Issue:

Estimated Enrollment: 664

Study Start Date: January 3, 2017

Phase: Phase 3

Eligibility:

  • Age: minimum 18 Years maximum N/A
  • Gender: All

Inclusion Criteria:

  • ECOG performance status of less than or equal to (
  • Pathologically confirmed RCC with a component of either clear cell histology or sarcomatoid histology that has not been previously treated in the adjuvant or neoadjuvant setting and classified as being at high risk of RCC recurrence
  • Radical or partial nephrectomy with lymphadenectomy in select participants
  • Absence of residual disease and absence of metastasis, as confirmed by a negative baseline computed tomography (CT) of the pelvis, abdomen, and chest no more than 4 weeks prior to randomization. Confirmation of disease-free status will be assessed by an independent central radiologic review of imaging data.
  • Absence of brain metastasis, as confirmed by a negative CT with contrast or magnetic resonance imaging (MRI) scan of the brain, no more than 4 weeks prior to randomization. Applicable only to metastasectomy participants
  • Full recovery from nephrectomy or metastasectomy within 12 weeks from randomization following surgery

Exclusion Criteria:

  • Bilateral synchronous tumors with inheritable forms of RCC including von Hippel-Lindau
  • Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatment
  • Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 28 days or five half-lives of the investigational agent, whichever is longer, prior to enrollment
  • Malignancies other than RCC within 5 years prior to Cycle 1, Day 1
  • History of autoimmune disease
  • Participants with prior allogeneic stem cell or solid organ transplantation
  • History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan
  • Positive test for HIV
  • Participants with active hepatitis B or hepatitis C
  • Active tuberculosis
  • Severe infections within 4 weeks prior to randomization including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia
  • Major surgical procedure within 4 weeks prior to randomization or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis
  • Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1
  • Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications
  • Prior treatment with cluster of differentiation (CD)137 agonists, anti-cytotoxic T-lymphocyte-associated protein-4 (anti-CTLA-4), anti-programmed death-1 (anti-PD−1), or anti-programmed death-ligand 1 (anti-PD-L1) therapeutic antibody or pathway-targeting agents
  • Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin-2) within 6 weeks or five half-lives of the drug, whichever is shorter, prior to randomization
  • Treatment with systemic immunosuppressive medications (including but not limited to corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti−tumor necrosis factor agents) within 2 weeks prior to randomization or anticipated need for systemic immunosuppressive medications during the study

Contact:

  • Reference Study ID Number: WO39210 www.roche.com/about_roche/roche_worldwide.htm
  • 888-662-6728 (U.S. and Canada)

Locations:

  • Banner MD Anderson Cancer Center
  • Gilbert Arizona 85234 United States
  • Mayo Clinic- Scottsdale
  • Scottsdale Arizona 85259 United States
  • City of Hope National Medical Center
  • Duarte California 91010 United States
  • Moores Cancer Center at UC San Diego Health
  • La Jolla California 92093 United States
  • City of Hope, Antelope Valley
  • Lancaster California 93534 United States
  • Cedars-Sinai Medical Center
  • Los Angeles California 90048 United States
  • UCLA Urology; Urology
  • Los Angeles California United States
  • University of California Irvine Medical Center
  • Orange California 92868 United States
  • City of Hope; Rancho Cucamonga
  • Rancho Cucamonga California 91730 United States
  • City of Hope-South Pasadena
  • South Pasadena California 91030 United States
  • University of Colorado Cancer Center
  • Aurora Colorado 80045 United States
  • The Urology Center of Colorado
  • Denver Colorado 80211 United States
  • Yale School of Medicine
  • New Haven Connecticut 06510 United States
  • Florida Cancer Specialists-Broadway, Fort Myers
  • Fort Myers Florida 33908 United States
  • University of Florida
  • Gainesville Florida 32607 United States
  • Mayo Clinic-Jacksonville
  • Jacksonville Florida 32224 United States
  • Univ of Miami, School of Med; Hem/Onc
  • Miami Florida 33136 United States
  • Moffitt Cancer Center
  • Tampa Florida 33647 United States
  • Emory Uni - Winship Cancer Center; Hematology/Oncology
  • Atlanta Georgia 30322 United States
  • Emory University Clinic
  • Atlanta Georgia 30322 United States
  • The University of Chicago Biological Sciences; Dept. of Medicine, Section of Hematology/Oncology
  • Chicago Illinois 60637 United States
  • Loyola University Medical Center, Cardinal Bernardin Cancer Center
  • Maywood Illinois 60151 United States
  • University of Iowa Hospitals & Clinics; Internal Medicine
  • Iowa City Iowa 52242 United States
  • Norton Cancer Institute
  • Louisville Kentucky 40202 United States
  • Tulane Uni Health Sciences Center
  • New Orleans Louisiana 70112 United States
  • Ochsner Clinic Foundation
  • New Orleans Louisiana 70121 United States
  • New England Cancer Specialists
  • Scarborough Maine 04074 United States
  • Chesapeake Urology Research Associates
  • Towson Maryland 21204 United States
  • Mayo Clinic - Rochester
  • Rochester Minnesota 55905 United States
  • Sarah Cannon Research Institute - Kansas City - HCA Midwest Health
  • Kansas City Missouri 64132 United States
  • Southeast Nebraska Cancer Center;; Southeast Nebraska Hematology and Oncology
  • Lincoln Nebraska 68510 United States
  • Garden State Urology
  • Whippany New Jersey United States
  • New York Oncology Hematology at Albany Medical Center
  • Albany New York 12208 United States
  • New York Oncology Hematology, P.C.
  • Albany New York 12208 United States
  • Bellevue Hospital
  • New York New York 10016 United States
  • Laura and ISAAC Perlmutter Cancer Center at NYU Langone.
  • New York New York 10016 United States
  • Mount SInai Medical Center
  • New York New York 10029 United States
  • Columbia University Medical Center
  • New York New York 10032 United States
  • University of Rochester Medical Center; Urology
  • Rochester New York 14642 United States
  • Stony Brook University Medical Center
  • Stony Brook New York 11794 United States
  • SUNY Upstate Medical University
  • Syracuse New York 13210 United States
  • University of North Carolina at Chapel Hill
  • Chapel Hill North Carolina 27514 United States
  • Levine Cancer Institute
  • Charlotte North Carolina 28204 United States
  • Duke Cancer Center
  • Durham North Carolina 27710 United States
  • Fairview Hospital; Cleveland Clinic Cancer Center
  • Cleveland Ohio 44111 United States
  • Cleveland Clinic Foundation; Hematology and Oncology
  • Cleveland Ohio 44195 United States
  • Hillcrest Hospital; Hirsch Cancer Center
  • Mayfield Heights Ohio 44124 United States
  • University of Oklahoma; Stephenson Oklahoma Canc Ctr
  • Oklahoma City Oklahoma 73104 United States
  • Oregon Health & Science Uni
  • Portland Oregon 97239 United States
  • Penn State Hershey Cancer Institute
  • Hershey Pennsylvania 17033 United States
  • Lancaster Urology
  • Lancaster Pennsylvania 17604 United States
  • Thomas Jefferson University Hospital;Medical Oncology
  • Philadelphia Pennsylvania 19107 United States
  • Fox Chase Cancer Center; Hematology/Oncology
  • Philadelphia Pennsylvania 19111 United States
  • UPMC Cancer Centers
  • Pittsburgh Pennsylvania 15232 United States
  • Carolina Urologic Research Center
  • Myrtle Beach South Carolina 29572 United States
  • Sanford Cancer Cnt Onco Clinic
  • Sioux Falls South Dakota 57104 United States
  • Erlanger Health Systems
  • Chattanooga Tennessee 37403 United States
  • Urology Associates of Kingsport, P.C.
  • Kingsport Tennessee United States
  • Sarah Cannon Research Institute
  • Nashville Tennessee 37203 United States
  • Vanderbilt University Medical Center; Vanderbilt University
  • Nashville Tennessee 37232 United States
  • University of Texas Southwestern Medical Center
  • Dallas Texas 75390 United States
  • MD Anderson Cancer Center
  • Houston Texas 77030-4095 United States
  • University of Utah; Huntsman Cancer Hospital
  • Salt Lake City Utah 84112 United States
  • Seattle Cancer Care Alliance
  • Seattle Washington 98109 United States
  • West Virginia University Hospitals Inc
  • Morgantown West Virginia 26056 United States
  • Hospital Britanico; Oncologia
  • Buenos Aires C1280AEB Argentina
  • Hospital Aleman
  • Caba C1118AAT Argentina
  • Centro Oncologico Riojano Integral (CORI)
  • La Rioja F5300COE Argentina
  • Calvary Mater Newcastle; Medical Oncology
  • Waratah New South Wales 2298 Australia
  • Royal Brisbane & Women's Hosp; Cancer Care Serv
  • Herston Queensland 4029 Australia
  • Ashford Cancer Center Research
  • Kurralta Park South Australia 5037 Australia
  • Austin Hospital; Medical Oncology
  • Heidelberg Victoria 3084 Australia
  • LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie
  • Graz 8036 Austria
  • Ordensklinikum Linz Elisabethinen; Abteilung für Urologie und Andrologie
  • Linz 4020 Austria
  • Landeskrankenhaus Salzburg; Universitätsklinik für Urologie und Andrologie der PMU
  • Salzburg 5020 Austria
  • Medizinische Universität Wien; Univ.Klinik für Innere Medizin I
  • Wien 1090 Austria
  • Cliniques Universitaires St-Luc
  • Bruxelles 1200 Belgium
  • Grand Hôpital de Charleroi Notre Dame
  • Charleroi 6000 Belgium
  • AZ Groeninge
  • Kortrijk 8500 Belgium
  • UZ Leuven Gasthuisberg
  • Leuven 3000 Belgium
  • CHU UCL Mont-Godinne
  • Mont-godinne 5530 Belgium
  • Cetus Hospital Dia Oncologia
  • Belo Horizonte MG 30110-022 Brazil
  • Hospital Luxemburgo; Oncologia
  • Belo Horizonte MG 31190-131 Brazil
  • Hospital Erasto Gaertner
  • Curitiba PR 81520-060 Brazil
  • Hospital das Clinicas - UFRGS
  • Porto Alegre RS 90035-003 Brazil
  • Hospital Sao Lucas - PUCRS
  • Porto Alegre RS 90610-000 Brazil
  • Instituto do Cancer do Estado de Sao Paulo - ICESP
  • Sao Paulo SP 01246-000 Brazil
  • Hospital Alemao Oswaldo Cruz
  • Sao Paulo SP 01323-903 Brazil
  • Tom Baker Cancer Centre-Calgary
  • Calgary Alberta T2N 4N2 Canada
  • Cross Cancer Institute
  • Edmonton Alberta T6G 1Z2 Canada
  • Bcca - Cancer Center Southern Interior
  • Kelowna British Columbia V1Y 5L3 Canada
  • BCCA-Vancouver Cancer Centre
  • Vancouver British Columbia V5Z 4E6 Canada
  • Queen Elizabeth II Health Sciences Centre; Oncology
  • Halifax Nova Scotia B3H 2Y9 Canada
  • Hamilton Health Sciences - Juravinski Cancer Centre
  • Hamilton Ontario L8V 5C2 Canada
  • The Ottawa Hospital Cancer Centre; Oncology
  • Ottawa Ontario K1H 8L6 Canada
  • North York General Hospital; Inpatient Pharmacy
  • Toronto Ontario M2K 1E1 Canada
  • Sunnybrook Odette Cancer Centre
  • Toronto Ontario M4N 3M5 Canada
  • Princess Margaret Cancer Center
  • Toronto Ontario M5G 1Z5 Canada
  • McGill University Health Center
  • Montreal Quebec H4A 3J1 Canada
  • CHUS (Centre Hospitalier Universitaire de Sherbrooke)
  • Sherbrooke Quebec J1H 5N4 Canada
  • Centre Hospitalier universitaire de Québec/ Hotel Dieu de Québec
  • Quebec G1R 3S1 Canada
  • Bradford Hill Centro de Investigaciones Clinicas; Bradford Hill Centro de Investigaciones Clinicas
  • Recoleta 8420383 Chile
  • Sociedad de Investigaciones Medicas Ltda (SIM)
  • Temuco 4810469 Chile
  • ONCOCENTRO APYS; Oncología
  • Vina Del Mar 2520598 Chile
  • Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)
  • Nanjing City 210029 China
  • Jiangsu Cancer Hospital
  • Nanjing 210009 China
  • Fudan University Shanghai Cancer Center; Medical Oncology
  • Shanghai 200032 China
  • Masarykuv onkologicky ustav
  • Brno 656 53 Czechia
  • Fakultni nemocnice Olomouc; Onkologicka klinika
  • Olomouc 779 00 Czechia
  • General University Hospital; CLINIC OF ONCOLOGY
  • Praha 2 128 08 Czechia
  • Thomayerova nemocnice
  • Praha 4 - Krc 140 59 Czechia
  • Fakultni nemocnice Kralovske Vinohrady
  • Praha 110 34 Czechia
  • Aarhus Universitetshospital; Kræftafdelingen
  • Aarhus N 8200 Denmark
  • Herlev Hospital; Onkologisk afdeling
  • Herlev 2730 Denmark
  • Odense Universitetshospital, Onkologisk Afdeling R
  • Odense C 5000 Denmark
  • CHU d'Angers
  • Angers 49033 France
  • CHU Henri Mondor; Service d'Oncologie Medicale
  • Creteil 94010 France
  • CHU Grenoble Hopital Albert Michallon; Urologie et Transplantation rénale
  • La Tronche 38700 France
  • Polyclinique de Limoges - Site Chenieux; Oncologie Medicale
  • Limoges 87039 France
  • CHU de Nantes - Hotel Dieu
  • Nantes 44093 France
  • Institut Mutualiste Montsouris; Oncologie
  • Paris 75674 France
  • CHU Pontchaillou
  • Rennes 35000 France
  • CHU de Rouen - Hôpital Charles Nicolle
  • Rouen 76031 France
  • Nouvel Hopital Civil - CHU Strasbourg; Urologie
  • Strasbourg 67091 France
  • Institut Gustave Roussy
  • Villejuif 94805 France
  • Universitätsklinikum "Carl Gustav Carus"; Klinik und Poliklinik für Urologie
  • Dresden 01307 Germany
  • Kliniken Essen-Mitte; Klinik für Urologie, Kinderurologie und Urologische Onkologie
  • Essen 45136 Germany
  • Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II
  • Hamburg 20246 Germany
  • Medizinische Hochschule; Zentrum Innere Medizin; Abt. Hämatologie u. Onkologie
  • Hannover 30625 Germany
  • Universitatsklinik Heidelberg; Universitätshautklinik und Nationales Centrum für Tumorerkrankungen
  • Heidelberg 69120 Germany
  • Universitätsklinikum des Saarlandes; Klinik für Urologie und Kinderurologie
  • Homburg/Saar 66424 Germany
  • Uniklinik Köln, Klinik für Urologie, Uro-Onkologie und spezielle urologische Chirurgie
  • Köln 50937 Germany
  • Klinikum rechts der Isar der TU München; Urologische Klinik und Poliklinik
  • München 81675 Germany
  • Universitätsklinikum Tübingen; Klinik für Urologie
  • Tübingen 72076 Germany
  • Universitätsklinikum Ulm; Klinik für Urologie
  • Ulm 89081 Germany
  • Cork Uni Hospital; Oncology Dept
  • Cork Ireland
  • Adelaide & Meath Hospital, Dublin, Incorporating the National Children's Hospital; Oncology Day Unit
  • Dublin 24 Ireland
  • Soroka Medical Center; Oncology Dept
  • Beer Sheva 8410101 Israel
  • Rambam Health Care Campus; Oncology
  • Haifa 3109601 Israel
  • Hadassah Ein Karem Hospital; Oncology Dept
  • Jerusalem 9112001 Israel
  • Meir Medical Center; Oncology
  • Kfar-Saba 4428164 Israel
  • Belinson Medical Center, Division of Oncology
  • Petach Tikva 4941492 Israel
  • Chaim Sheba medical center, Oncology division
  • Ramat Gan 5262000 Israel
  • Sourasky Medical Center; Oncology Department
  • Tel-Aviv 6423900 Israel
  • Az. Osp. Cardarelli; Divisione Di Oncologia
  • Napoli Campania 80131 Italy
  • Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica
  • Bologna Emilia-Romagna 40138 Italy
  • IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
  • Meldola Emilia-Romagna 47014 Italy
  • A.O. Universitaria Policlinico Di Modena; Oncologia
  • Modena Emilia-Romagna 41100 Italy
  • Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2
  • Milano Lombardia 20133 Italy
  • Fondazione IRCCS Policlinico San Matteo, Oncologia
  • Pavia Lombardia 27100 Italy
  • Istituti Clinici Scientifici Maugeri SpA-SB
  • Pavia Lombardia 27100 Italy
  • Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato;U.O.C. Oncologia
  • Arezzo Toscana 52100 Italy
  • IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Prima
  • Padova Veneto 35128 Italy
  • Nagoya University Hospital
  • Aichi 466-8560 Japan
  • Hirosaki University Hospital
  • Aomori 036-8563 Japan
  • Kyushu University Hospital
  • Fukuoka 812-8582 Japan
  • Hiroshima City Hiroshima Citizens Hospital
  • Hiroshima 730-8518 Japan
  • Kobe University Hospital
  • Hyogo 650-0017 Japan
  • University of Tsukuba Hospital
  • Ibaraki 305-8576 Japan
  • Kagoshima City Hospital
  • Kagoshima 890-8760 Japan
  • Mie University Hospital
  • Mie 514-8507 Japan
  • Niigata University Medical & Dental Hospital
  • Niigata 951-8520 Japan
  • Okayama University Hospital
  • Okayama 700-8558 Japan
  • Kindai University Hospital
  • Osaka 589-8511 Japan
  • Jichi Medical University Hospital
  • Tochigi 329-0498 Japan
  • Tokushima University Hospital
  • Tokushima 770-8503 Japan
  • Toranomon Hospital
  • Tokyo 105-8470 Japan
  • Tokyo Medical & Dental University Hospital
  • Tokyo 113-8519 Japan
  • Nippon Medical School Hospital
  • Tokyo 113-8603 Japan
  • Tokyo Women's Medical University Medical Center East
  • Tokyo 116-8567 Japan
  • The Cancer Institute Hospital of JFCR
  • Tokyo 135-8550 Japan
  • Keio University Hospital
  • Tokyo 160-8582 Japan
  • National Cancer Center; Neurology
  • Gyeonggi-do 10408 Korea, Republic of
  • Asan Medical Center - Oncology
  • Seoul 05505 Korea, Republic of
  • Samsung Medical Center - Neurology
  • Seoul 6351 Korea, Republic of
  • VU Medisch Centrum; VU University Medical Center
  • Amsterdam 1007 MB Netherlands
  • Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis
  • Amsterdam 1066 CX Netherlands
  • Academ Ziekenhuis Groningen; Medical Oncology
  • Groningen 9713 GZ Netherlands
  • UMC Radboud Nijmegen
  • Nijmegen 6500 HB Netherlands
  • Sint Franciscus Gasthuis; Inwendige Geneeskunde
  • Rotterdam 3045 PM Netherlands
  • St. Antonius locatie Leidsche Rijn
  • Utrecht 3543 AZ Netherlands
  • Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii
  • Krakow 31-531 Poland
  • Klinika Onkologii Klinicznej CO-I Kraków
  • Krakow Poland
  • Centrum Onkologii Ziemi Lubelskiej im. św. Jana z Dukli
  • Lublin 20-090 Poland
  • Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego
  • Poznan 60-570 Poland
  • Centralny Szpital Kliniczny MSWiA; Klinika Onkologii i Hematologii
  • Warsaw 02-507 Poland
  • Saint Elizabeth's Hospital
  • Warsaw 02-616 Poland
  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu
  • Wroclaw 50-556 Poland
  • Moscow City Clinical Hospital #57; Oncourology
  • Moskva Moskovskaja Oblast 105077 Russian Federation
  • Altai Region Oncology Dispensory; Oncology
  • Barnaul 656049 Russian Federation
  • Sverdlovsk Regional Clinical Hospital 1
  • Ekaterinburg 620102 Russian Federation
  • Ivanovo Regional Oncology Dispensary
  • Ivanovo 153040 Russian Federation
  • Blokhin Cancer Research Center; Urological Dept
  • Moscow 115478 Russian Federation
  • First Moscow State Medical University n.a. I.M. Sechenov
  • Moscow 119991 Russian Federation
  • P.A. Herzen Oncological Inst. ; Oncology
  • Moscow 125284 Russian Federation
  • City Clinical Oncology Hospital
  • Moscow 143423 Russian Federation
  • Privolzhsk Regional Medical Center
  • Nizhny Novgorod 603001 Russian Federation
  • City Clinical Oncology Dispensary
  • Saint-Petersburg 197022 Russian Federation
  • Multidisciplinary clinic Reaviz
  • Samara 443011 Russian Federation
  • Scientific Research Oncology Institute named after N.N. Petrov; Oncology
  • St. Petersburg 197758 Russian Federation
  • Clinic for Urology, Clinical Center of Serbia; Clinic for Urology
  • Belgrade 11000 Serbia
  • Clinic for Urology; Military Medical Academy
  • Belgrade 11000 Serbia
  • Institute for Oncology and Radiology of Serbia; Medical Oncology
  • Belgrade 11000 Serbia
  • Oncology Institute of Vojvodina
  • Sremska Kamenica 21204 Serbia
  • Hospital Univ. Central de Asturias; Servicio de Oncologia
  • Oviedo Asturias 33011 Spain
  • Hospital Universitario Reina Sofia; Servicio de Oncologia
  • Córdoba Cordoba 14004 Spain
  • Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia
  • Santiago de Compostela LA Coruña 15706 Spain
  • Hospital Univ Vall d'Hebron; Servicio de Oncologia
  • Barcelona 08035 Spain
  • Hospital Clínic i Provincial; Servicio de Oncología
  • Barcelona 08036 Spain
  • Institut Catala d Oncologia Hospital Duran i Reynals
  • Barcelona 08908 Spain
  • Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
  • Madrid 28007 Spain
  • Hospital Ramon y Cajal; Servicio de Oncologia
  • Madrid 28034 Spain
  • Hospital Universitario Clínico San Carlos; Servicio de Oncologia
  • Madrid 28040 Spain
  • Hospital Universitario 12 de Octubre; Servicio de Oncologia
  • Madrid 28041 Spain
  • China Medical University Hospital; Urology
  • Taichung 40447 Taiwan
  • Taichung Veterans General Hospital; Division of Urology
  • Taichung 407 Taiwan
  • National Taiwan University Hospital, Department of Urology
  • Taipei 10048 Taiwan
  • TAIPEI VETERANS GENERAL HOSPITAL, Urology
  • Taipei 11217 Taiwan
  • Chang Gung Medical Foundation-Linkou, Urinary Oncology
  • Taoyuan 333 Taiwan
  • Division of Urological surgery; Department of surgery, Chulalongkorn University
  • Bangkok 10330 Thailand
  • Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc
  • Bangkok 10400 Thailand
  • Maharaj Nakorn Chiangmai Hospital; Department of Surgery/ Urology unit
  • Chiangmai 50200 Thailand
  • Adana City Hospital, Medical Oncology
  • Adana 01060 Turkey
  • Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology
  • Adana 01250 Turkey
  • Gazi University Medical Faculty; Department of İnternal Medicine
  • Ankara 06500 Turkey
  • Ankara Uni School of Medicine; Medical Oncology
  • Ankara 06590 Turkey
  • Trakya University Medical Faculty
  • Edirne 22030 Turkey
  • Hacettepe Uni Medical Faculty Hospital; Oncology Dept
  • Sıhhiye, Ankara 06100 Turkey
  • Regional Clinical Center of Urology and Nephrology n.a. V.I. Shapoval Department of Urology #4
  • Kharkiv Kharkiv Governorate 61037 Ukraine
  • CI Dnipropetrovsk CMCH #4 MA of MOHU Ch of Oncology and MR
  • Dnipropetrovsk 49102 Ukraine
  • GU "Institution of urology of Academy Medical science of Ukraine"
  • Kiev 04053 Ukraine
  • National Institute of Cancer
  • Kyiv 03022 Ukraine
  • Lviv State Oncology Regional Treatment and Diagnostic Centre; Department of hemotherapy
  • Lviv 79031 Ukraine
  • Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary
  • Sumy 40005 Ukraine
  • Zaporizhzhia Regional Clinic
  • Zaporizhzhia 69600 Ukraine
  • Leicester Royal Infirmary
  • Leicester LE1 5WW United Kingdom
  • Royal Free Hospital
  • London NW3 2QS United Kingdom
  • Christie Hospital
  • Manchester M20 3BG United Kingdom
  • Freeman Hospital
  • Newcastle upon Tyne NE7 7DN United Kingdom
  • Weston Park Hospital
  • Sheffield S10 2SJ United Kingdom
  • Singleton Hospital; Pharmacy Department
  • Swansea SA2 8QA United Kingdom

View trial on ClinicalTrials.gov


E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe